This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Epigenetic Therapies And Technologies: World Market Prospects 2013-2023

6.1.1 LDTs vs. IVDs: Two Diagnostic Development Strategies

6.2 Epigenetic Diagnostics Marketed 2012

6.2.1 Epi proColon 2.0 (Epigenomics)

6.2.1.1 ColoVantage (Quest Diagnostics)

6.2.1.2 Septin9 LDT (ARUP Laboratories)

6.2.2 ColoSure (LabCorp)

6.2.3 ConfirmMDx for Prostate Cancer (MDxHealth)

6.2.3.1 Gene Methylation in Prostate Cancer (LabCorp)

6.2.4 Epi proLung (Epigenomics)

6.2.5 MGMT Gene Methylation Assay (LabCorp)

6.2.6 Bladder Cancer Testing with CertNDx (Predictive Biosciences)

6.3 Epigenetic Diagnostics Pipeline 2012

6.3.1 The Future of Colorectal Cancer Testing

6.3.1.1 Cologuard: Using More Biomarkers to Improve Sensitivity

6.3.1.2 Orion Colorectal Cancer Risk Test (Orion Genomics)

6.3.1.3 PredictMDx (MDxHealth)

6.3.2 New Prognostic Tools in Development for Prostate Cancer

6.3.3 Lung Cancer

6.3.3.1 Lung Cancer Screening Test (Orion Genomics)

6.3.3.2 ConfirmMDx and InformMDx (MDxHealth)

6.3.4 Future Developments in Bladder Cancer Testing

6.3.4.1 Bladder Cancer Screening Test (Orion Genomics)

6.3.5 Other Cancer Tests in Development 2012

6.3.5.1 PredictMDx for Brain Cancer LDT (MDxHealth)

6.3.5.2 Pancreatic Cancer Prognostic Test (PrognosDx Health)

6.4 Leading Epigenetic Diagnostic Developers 2012

6.4.1 Epigenomics Markets Multiple Tests in the EU

6.4.1.1 Low Revenue in the EU 2010-2012

6.4.2 Exact Sciences and Colorectal Cancer Screening

6.4.3 MDxHealth: Targeting the US Diagnostics Market

6.4.3.1 Strong Revenue Growth 2009-2011

6.4.4 Orion Genomics Has Discovered More Than 100 Biomarkers

6.4.5 Predictive Biosciences

6.4.6 PrognosDx Health: Developing Epigenetic Prognostics

7. Epigenetic Technologies Market 2013-2023

7.1 Epigenetic Technology and Services Market 2013-20237.1.1 Outsourcing Epigenetic Discovery and Analysis7.2 Next Generation Sequencing (NGS)7.2.1 Lower Costs and Higher Speed for Expanded Research7.2.2 Bottlenecks in Bioinformatics7.2.3 Single Molecule Sequencing to Compete with NGS7.3 Future Developments in Chromatin Immunoprecipitation7.3.1 Considerations for ChIP-Seq7.4 Future Developments in Bisulphite Screening7.4.1 Techniques for Researching 5hmC Developed 20127.5 High Throughput Screening for Epigenetics7.6 Leading Providers of Epigenetic Technologies 20127.6.1 Active Motif7.6.2 Agilent Technologies: Measurement Tools for Epigenetic Research7.6.3 Diagenode7.6.4 DiscoveRx: Providing Tools to Research New Epigenetic Pathways7.6.5 EMD Millipore7.6.6 Epigentek Specialises in Epigenetic Technologies and Services7.6.7 Epiontis: Epigenetics in Regenerative Medicine7.6.8 Life Technologies: Cutting the Cost of NGS7.6.9 Qiagen is Developing Epigenetic Technologies and Diagnostics7.6.10 Roche

8. Research and Product Development Strategies in Epigenetics 2013-2023

8.1 The Epigenetic Therapies and Technologies Market by Disease 2013-2023

6 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs